Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults.

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24, 2025

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23, 2025

Long-Term Durability and Cost-Effectiveness of Adalimumab Biosimilars in Pediatric IBD

June 22, 2025

The Top 5 Biosimilars Articles for the Week of June 16

June 20, 2025

BioRationality: A Socratic Analysis of IQVIA Report on Biosimilars

February 17th 2025

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, gives his opinion on how the recent IQVIA report “Assessing the Biosimilar Void in the US” could be improved for the future.

Enhancing Biosimilar Adoption in Value-Based Oncology Care

February 16th 2025

By Travis Brewer

Video

Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in making cancer care more affordable and accessible, as well as the need for greater payer trust in oncologists’ treatment decisions.

Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD

February 15th 2025

By Deana Ferreri, PhD

Article

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.

Biosimilars Fuel Price Cuts in European Insulin Glargine Markets

February 14th 2025

By Skylar Jeremias

Article

Although Lantus continues to lead the insulin glargine market globally, the rise of biosimilars like Abasaglar and Semglee has sparked significant price reductions, with some European countries seeing discounts of up to 42.3%.

The Top 5 Biosimilar Articles for the Week of February 10

February 14th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of February 10, 2025.

Robert F. Kennedy Jr Confirmed as HHS Secretary, Nearly Along Party Lines

February 13th 2025

By Christina Mattina

Article

The Senate voted 52-48 to confirm Robert F. Kennedy Jr as secretary of HHS, setting up the vaccine skeptic to carry out major changes in pursuit of his Make America Healthy Again agenda.

Psoriasis Biosimilars Saved VA $67 Million in 2023

February 12th 2025

By Skylar Jeremias

Article

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high costs of biologic therapies to treat chronic disease.

The Future of Pharmacy: Trends, Threats, Transformations

February 11th 2025

By Cameron Santoro

Article

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future of drug access and affordability for patients across the nation.

Welcome Wezlana: Using Adalimumab to Predict Ustekinumab Market Potential

February 10th 2025

By Dracey Poore

Article

2025 marks a pivotal year for biosimilars with Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey Poore, MS, of Cardinal Health.

Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals

February 9th 2025

By Skylar Jeremias

Podcast

In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.